Gyroscope Therapeutics Announces Appointments of Industry Veterans in Gene Therapy, Ophthalmology and Biopharmaceuticals to Its Board of Directors

Information and analysis earlier than you hear about it on CNBC and others. Declare your 1-week free trial to StreetInsider Premium here.

LONDON–(BUSINESS WIRE)–
Gyroscope Therapeutics Restricted, a clinical-stage retinal gene remedy firm, immediately introduced that Jennifer Cook dinner, David Fellows and Renée Galá have been appointed to the Gyroscope Board of Administrators, efficient instantly.

“I’m very happy to welcome Jennifer, David, and Renée, three extraordinarily achieved executives with in depth biopharmaceutical backgrounds, to our board of administrators,” mentioned Khurem Farooq, Chief Government Officer. “We look ahead to their priceless contributions and distinctive views as we proceed our work to develop gene remedy past uncommon illness with the aim of delivering new medicines to individuals with retinal ailments.”

Ms. Cook dinner was most just lately the Chief Government Officer of GRAIL, a healthcare firm centered on the early detection of most cancers. Previous to becoming a member of GRAIL, she held plenty of management positions throughout her 25-year tenure with Roche/Genentech, together with main Roche Prescription drugs’ European industrial enterprise, International Medical Operations, U.S. and International Product Portfolio Administration, the U.S. Immunology and Ophthalmology Enterprise Unit and Market Improvement. She at the moment serves on the boards of administrators of Denali Therapeutics, BridgeBio Pharma and Ambys Medicines. Ms. Cook dinner holds a B.A. in human biology and an M.S. in biology from Stanford College, in addition to an MBA from the Haas College of Enterprise on the College of California, Berkeley.

Mr. Fellows was most just lately the Chief Government Officer of Nightstar Therapeutics, a retinal gene remedy firm acquired by Biogen in 2019. Previous to becoming a member of Nightstar, he was the Vice President of Johnson & Johnson’s Imaginative and prescient Care Franchise the place he led the worldwide advertising, new product and licensing actions. Earlier than becoming a member of Johnson & Johnson, Mr. Fellows held management positions at Allergan, Inc., for 25 years the place he served primarily in gross sales and advertising in plenty of capacities, together with Regional President, Company Vice President, and Senior Vice President throughout North America, Europe and Asia. He at the moment serves because the chairman of the board for Oxular Restricted and is a board member of the Glaucoma Basis. Mr. Fellows holds a B.A. in psychology from Butler College.

Ms. Galá at the moment serves because the Government Vice President and Chief Monetary Officer of Jazz Prescription drugs, a worldwide biopharmaceutical firm. Previous to becoming a member of Jazz, she served because the Chief Monetary Officer of GRAIL. Earlier than becoming a member of GRAIL, Ms. Galá served because the Senior Vice President and Chief Monetary Officer of Theravance Biopharma, the place she led the corporate’s spin-out transaction from Innoviva, Inc. Ms. Galá has additionally served in international treasury, pharmaceutical gross sales and company technique/enterprise growth at Eli Lilly and Firm. Previous to becoming a member of Eli Lilly, she spent seven years within the vitality trade in positions centered on company finance, undertaking finance and mergers and acquisitions. She at the moment serves on the board of administrators of Gossamer Bio the place she chairs its audit committee. Ms. Galá holds a B.S. in arithmetic from Vanderbilt College and an MBA from Columbia Enterprise College.

About Gyroscope: Imaginative and prescient for Life

Gyroscope Therapeutics is a clinical-stage retinal gene remedy firm creating gene remedy past uncommon illness to deal with a number one explanation for blindness, dry age-related macular degeneration (AMD). Our lead investigational gene remedy, GT005, is a one-time remedy delivered beneath the retina. GT005 is designed to revive stability to an overactive complement system by rising manufacturing of the Complement Issue I protein. GT005 is at the moment being evaluated in a Part I/II medical trial referred to as FOCUS and Part II medical trials referred to as EXPLORE and HORIZON.

Syncona Ltd, our lead investor, helped us create a number one retinal gene remedy firm combining discovery, analysis, drug growth, a producing platform and surgical supply capabilities. Headquartered in London with places in Philadelphia and San Francisco, our mission is to protect sight and combat the devastating influence of blindness. For extra info go to: www.gyroscopetx.com and observe us on Twitter (@GyroscopeTx) and on LinkedIn.